Validation of a novel Guideline Directed Medical Therapy (GDMT) scoring tool to optimize therapy for patients with heart failure with reduced ejection fraction (HFrEF)
Open Access
- 2 June 2026
- journal article
- Published by Wolters Kluwer Health in Annals of Clinical Cardiology
- Vol. 8 (2) , 96-101
Abstract
Background: The mortality benefit of guideline-directed medical therapy (GDMT) for patients with heart failure with reduced ejection fraction (HFrEF) is well established. However, contemporary registry data consistently demonstrates substantial gaps in GDMT optimization. A standardized tool to quantify GDMT optimization and target dose achievement may help identify treatment deficits, guide clinical decision-making, and improve associated patient outcomes. Methods: This retrospective, single-center observational study evaluated the internal validity of a novel GDMT scoring tool to quantify GDMT optimization. Adult patients admitted between September 2022 and September 2023 with HFrEF and outpatient follow-up were included. The primary analysis assessed the association between GDMT optimization at 30 days and the risk of 90-day all-cause hospitalization using multivariable logistic regression. Secondary analyses described GDMT optimization rates at 30 days, quadruple therapy rates, and associations between GDMT optimization and 90-day HF hospitalization and all-cause mortality. Results: Eighty-nine patients met inclusion criteria. At 30 days, 76% of patients (n= 68) achieved a GDMT score of ≥ 5 and 24% (n= 21) had a suboptimal GDMT score of P=0.008 ) though no significant differences were observed for HF hospitalizations (OR 0.55 CI 0.17-1.85, P=0.33 ) or all-cause mortality ( P=0.997 ). Conclusion: An optimized GDMT score of ≥ 5 at 30 days was associated with reduced odds of all-cause readmissions at 90 days ( P=0.008 ).Keywords
This publication has 23 references indexed in Scilit:
- A Scoring Evaluation for the Practical Introduction of Guideline-Directed Medical Therapy in Heart Failure PatientsESC Heart Failure, 2023
- The Evidence for Pharmacist Care in Outpatients with Heart Failure: A Systematic Review and Meta-AnalysisESC Heart Failure, 2021
- Association of Optimal Implementation of Sodium-Glucose Cotransporter 2 Inhibitor Therapy With Outcome for Patients With Heart FailureJAMA Cardiology, 2020
- Effectiveness of the Pharmacist-Involved Multidisciplinary Management of Heart Failure to Improve Hospitalizations and Mortality Rates in 4630 Patients: A Systematic Review and Meta-Analysis of Randomized Controlled TrialsJournal of Cardiac Failure, 2019
- Effect on Mortality of Higher Versus Lower β-Blocker (Metoprolol Succinate or Carvedilol) Dose in Patients With Heart FailureThe American Journal of Cardiology, 2018
- Medical Therapy for Heart Failure With Reduced Ejection FractionJACC, 2018
- Heart Failure Oral Therapies at Discharge are Associated with Better Outcome in Acute Heart Failure: A Propensity-Score Matched StudyEuropean Journal of Heart Failure, 2017
- Heart Rate and Rhythm and the Benefit of Beta-Blockers in Patients With Heart FailureJACC, 2017
- Pharmacist Care of Patients With Heart FailureA Systematic Review of Randomized TrialsArchives of internal medicine (1960), 2008
- Effects of Controlled-Release Metoprolol on Total Mortality, Hospitalizations, and Well-being in Patients With Heart FailureJAMA, 2000